Holding(s) in Company (6235B)
February 22 2011 - 3:23AM
UK Regulatory
TIDMGWP
RNS Number : 6235B
GW Pharmaceuticals PLC
22 February 2011
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
-----------------------------------------------
1. Identity of the issuer or the GW Pharmaceuticals plc
underlying issuer of existing shares
to which voting rights are attached:
-------------------------------------- -----------------------
2 Reason for the notification (please tick the appropriate box
or boxes):
-------------------------------------------------------------------------
An acquisition or disposal of voting rights X
----------------------------------------------------------------- ------
An acquisition or disposal of qualifying financial instruments
which may result in the acquisition of shares already
issued to which voting rights are attached
----------------------------------------------------------------- ------
An acquisition or disposal of instruments with similar
economic effect to qualifying financial instruments
----------------------------------------------------------------- ------
An event changing the breakdown of voting rights
----------------------------------------------------------------- ------
Other (please
specify):
----------------- ---------------------------------------------- ------
3. Full name of person(s) subject Great Point Partners LLC
to the notification obligation:
------------------------------------ --------------------------------
4. Full name of shareholder(s) (if Biomedical Value Fund, L.P.
different from 3.): Biomedical Institutional Value
Fund, L.P.
Biomedical Offshore Value
Fund Ltd.
------------------------------------ --------------------------------
5. Date of the transaction and date January 7, 2011
on which the threshold is crossed
or reached:
------------------------------------ --------------------------------
6. Date on which issuer notified: February 17, 2011
------------------------------------ --------------------------------
7. Threshold(s) that is/are crossed Less than 5%
or reached:
------------------------------------ --------------------------------
8. Notified details:
---------------------------------------------------------------------------------------------
A: Voting rights attached to shares
---------------------------------------------------------------------------------------------
Class/type of
shares if
possible Situation previous
using the to the triggering Resulting situation after the triggering
ISIN CODE transaction transaction
-------------- ---------------------- -----------------------------------------------------
Number
Number of
of Voting Number of Number of voting % of voting
Shares Rights shares rights rights
-------------- ---------- ---------- ---------- --------------------- ------------------
Direct Direct Indirect Direct Indirect
-------------- ---------- ---------- ---------- ---------- --------- ------- ---------
Ordinary
shares 6,602,000 6,602,000 5,852,000 5,852,000 - 4.45% -
---------- ---------- ---------- ---------- --------- ------- ---------
GB0030544687
-------------- ---------- ---------- ---------- ---------- --------- ------- ---------
B: Qualifying Financial Instruments
------------------------------------------------------------------------------
Resulting situation after the triggering transaction
------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date Conversion rights that may rights
Period be acquired if
the instrument
is exercised/
converted.
------------------ ----------- ------------ ----------------- ------------
C: Financial Instruments with similar economic effect to Qualifying
Financial Instruments
-------------------------------------------------------------------------------
Resulting situation after the triggering transaction
-------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of % of voting
financial price date Conversion voting rights
instrument period rights
instrument
refers to
----------- --------- ----------- ----------- ----------- ----------------
Nominal Delta
----------- --------- ----------- ----------- ----------- -------- ------
Total (A+B+C)
------------------------------------------------------
Number of voting rights Percentage of voting rights
------------------------ ----------------------------
5,852,000 4.45%
------------------------ ----------------------------
9. Chain of controlled undertakings through which the voting rights and/or
the
financial instruments are effectively held, if applicable:
---------------------------------------------------------------------------
Biomedical Value Fund, L.P
165 Mason Street
3(rd) Floor, Greenwich
CT 06830
Biomedical Institutional Value Fund, L.P
165 Mason Street
3(rd) Floor, Greenwich
CT 06830
Biomedical Offshore Value Fund, Ltd
165 Mason Street
3(rd) Floor, Greenwich
CT 06830
Proxy Voting:
----------------------------------------
10. Name of the proxy holder: -
------------------------------------
11. Number of voting rights proxy -
holder will cease to hold:
------------------------------------
12. Date on which proxy holder will -
cease to hold voting rights:
------------------------------------
13. Additional information:
------------------------------------ --------------------------
Ron Panzier
Chief Financial Officer
14. Contact name: Great Point Partners LLC
------------------------------------ --------------------------
15. Contact telephone number: 001-203-971-3300
------------------------------------ --------------------------
16. Contact number at the Company: Adam George
Company Secretary
+ 44 (0) 1980 557 000
------------------------------------ --------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLEAPAAAAAFEEF
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2024 to Aug 2024
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Aug 2023 to Aug 2024
